Evidence map›Paper›PMID 40164587›Full record

ArticleCell death & disease2025

Modulation of CREB3L2-ATF4 heterodimerization via proteasome inhibition and HRI activation in Alzheimer's disease pathology.

Krystal Herline-Killian, Michaela M Pauers, Jessica E Lipponen, Michael A Zrzavy, Cláudio Gouveia Roque, Ethan P McCurdy, Kyung Min Chung, Ulrich Hengst

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Krystal Herline-KillianThe Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Michaela M PauersDoctoral Program in Neurobiology and Behavior, Columbia University, New York, NY, USA.
Jessica E LipponenGraduate Program in Pathobiology and Mechanisms of Disease, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Michael A ZrzavyThe Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Cláudio Gouveia RoqueThe Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Ethan P McCurdyIntegrated Program in Cellular, Molecular and Biomedical Studies, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Kyung Min ChungThe Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Ulrich HengstThe Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA. uh2112@cumc.columbia.edu.ORCID http://orcid.org/0000-0002-8061-2861

Funding

Training in Cellular, Molecular and Biomedical Studies (CMBS)T32GM145766 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Rebecca Anne Haeusler, RONALD K. LIEM · 2022 to 2026
$4.1M
ADVANCED GRADUATE TRAINING PROGRAM IN NEUROBIOLOGY & BEHAVIORT32NS064928 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HENGST, ULRICH · 2010 to 2024
$3.0M
Neuroprotection by a Secreted Component of the Cellular Stress ResponseR01NS121337 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Ulrich Hengst · 2022 to 2026
$3.0M
A transcription factor complex specifically induced in neurodegenerationR01NS109607 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HENGST, ULRICH · 2018 to 2022
$2.3M
Alzheimer's Association AARF-17-533511-RAPIDBrightFocus Foundation (BrightFocus) A2021030SNIGMS NIH HHS T32 GM145766NINDS NIH HHS R01 NS109607NINDS NIH HHS R01 NS121337NINDS NIH HHS T32 NS064928U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R01NS109607U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R01NS121337U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) T32NS064928
6 · The paper itself

Abstract

Alzheimer's disease (AD) pathology includes transcriptional changes in the neurons, which are in part caused by the heterodimerization of two stress response transcription factors, CREB3L2 and ATF4. We investigated the role of proteasome inhibition and the eIF2α-kinase HRI in the formation of CREB3L2-ATF4 in neurons exposed to soluble oligomeric Aβ

Indexed as

Activating Transcription Factor 4Alzheimer DiseaseBasic-Leucine Zipper Transcription FactorseIF-2 KinaseProteasome Endopeptidase ComplexProteasome InhibitorsAmyloid beta-PeptidesAnimalsHumansNeuronsPeptide FragmentsProtein MultimerizationActivating Transcription Factor 4Amyloid beta-Peptidesamyloid beta-protein (1-42)ATF4 protein, humanBasic-Leucine Zipper Transcription FactorsCREB3L2 protein, humaneIF-2 KinasePeptide FragmentsProteasome Endopeptidase ComplexProteasome Inhibitors

Identifiers

PMID40164587
PMCPMC11958753

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.